Associations between serum biomarkers and non-alcoholic liver disease: Results of a clinical study of Mediterranean patients with obesity

Sara De Nucci¹, Fabio Castellana², Roberta Zupo², Luisa Lampignano², Martina Di Chito¹, Roberta Rinaldi¹, Vito Giannuzzi³, Raffaele Cozzolongo³, Giuseppina Piazzolla⁴, Gianluigi Giannelli³, Rodolfo Sardone² and Giovanni De Pergola¹*

Background: Transient elastography is an ultrasound-based method to detect non-alcoholic fatty liver disease (NAFLD). Despite the simultaneously rising prevalence of fatty liver and metabolic disease, further information about metabolic risk indicators of fatty liver is still necessary.

Methods: A Southern Italian population sample with obesity (N = 87) was cross-sectionally explored for associations among the presence of NAFLD, assessed by FibroScan, and clinical, biochemical and anthropometric parameters. Inclusion criteria were age > 18 years, BMI ≥ 25 kg/m², no ongoing supplemental or drug therapy, including oral contraceptives or osteoporosis medications; exclusion criteria were pregnancy, endocrinological diseases, cardiovascular diseases, neoplasia, renal or hepatic failure, hereditary thrombocytopenia, hepatitis B (HBV) or hepatitis C virus (HCV) infection, and excess alcohol consumption.

Results: The study sample featured a female predominance (67%, N = 60), age range 18–64 years, and 40% prevalence of NAFLD, in accordance with the fibroscan–measured controlled attenuation parameter (CAP) threshold value above 302 dB/m. Males were slightly more frequently affected by NAFLD (51.4% vs. 48.6%, p = 0.01). Insulin levels, insulin resistance (quantified by HOMA-IR), diastolic blood pressure, BMI, visceral adipose tissue (VAT), and waist circumference were significantly higher in the NAFLD subset compared to their counterparts (p < 0.01, p < 0.01, p = 0.05, p < 0.01, p < 0.01, p < 0.01, respectively). Uric acid (p < 0.01) also showed a positive trend in the
Introduction

Liver disease has emerged as one of the most troubling epidemiologic health outcomes of non-communicable disease burdens over the past decade (1). Now-a-days, liver epidemiology is shifting from viral hepatitis, that is well addressed by vaccines or drugs, to fatty liver disease, likely due to the increasing prevalence of metabolic syndrome. In this context, non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in developed countries, exceeding 25% among European adults (2). The highest prevalence has been reported in the Middle East and South America, reaching 70% in populations with obesity and diabetes (3, 4). Individuals with metabolic syndrome or its components are more frequently affected by fatty liver disease, clinically described as a spectrum of liver disease combined with metabolic and cardiovascular disorders (5). NAFLD is closely linked to abdominal obesity, diabetes, and dyslipidaemia, as well as with rising levels of clinical and molecular markers of insulin resistance and metabolic syndrome. To the point that, a group of hepatologists from around the world have lately suggested renaming NAFLD as MAFLD (metabolic associated fatty liver disease) (6).

Hepatic steatosis is defined as over 5% liver fat accumulation, not attributable to causes such as excessive alcohol consumption, viral infections, or medications (7, 8). Subcategories of NAFLD include histologic evidence of hepatic steatosis or non-alcoholic steatohepatitis (NASH), a condition of fat accumulation associated with lobular inflammation, with or without fibrosis (9). The prognosis of NAFLD can predict the risk of developing cirrhosis and hepatocellular carcinoma, but the cardiometabolic components are the leading causes of morbidity in these patients (5, 10).

However, since fatty liver is frequently a late-diagnosed and asymptomatic condition in developed countries, morbidity and mortality rates attributable to fatty liver are progressively increasing. In this worsening perspective, obesity phenotypes with excess visceral fat, that account for nearly 80% of fatty liver phenotypes, are more likely to favor liver injury (11). As regards the mechanisms responsible, an increased VAT release of proinflammatory cytokines and adipokines and the delivery of free fatty acids (FFA) into the portal and systemic circulation are the main pathogenic processes underlying NAFLD (12, 13).

For the diagnosis of NAFLD, staging and clinical management, the gold standard, i.e., liver biopsy, is too invasive for widespread use in clinical practice and, therefore, a non-invasive approach is recommended. Serum biomarkers include predictive models such as the hepatic steatosis index (HSI) (14) and the fatty liver index (FLI) (15). A large body of research has endorsed these scores, although they fail to provide further information about individuals with NAFLD. Our recent meta-analysis suggested that the FLI performs well in stratifying the risk of NAFLD but has less efficacy in excluding or diagnosing the condition (16). Instead, transient elastography (FibroScan) is a widely known ultrasound-based technique for use in clinical practice, supporting accurate and reliable assessment of liver steatosis across different populations (17, 18).

The present clinical cross-sectional study targeted a Southern Italian population with overweight and obesity, with the aim of investigating the association between the presence of NAFLD, assessed by the FibroScan ultrasound device, and clinical, biochemical, and anthropometric parameters.

Materials and methods

Study population and design

Patients were recruited from January to March 2022 at the National Institute of Gastroenterology “Saverio De Bellis” Research Hospital Outpatients Clinic of Internal Medicine and Geriatrics (Castellana Grotte, Bari, Apulia, Italy). Inclusion criteria were age over 18 years, BMI $\geq$ 25 kg/m$^2$, no ongoing integrative or drug therapy, including oral contraceptives or osteoporosis medications. Exclusion criteria were pregnancy,
FIGURE 1
Flowchart of the sample screening process.

any endocrinological disease (i.e., diabetes mellitus, hypo- or hyperthyroidism, hypopituitarism), chronic inflammatory disease, stable hypertension, angina pectoris, a history of stroke, transient ischemic attack, atrial fibrillation, heart attack, congenital heart disease, any major malignancy, renal or hepatic insufficiency, hereditary thrombocytopenia, hepatitis B (HBV) or hepatitis C virus (HCV) infection, and excessive alcohol consumption. In accordance with American and European guidelines (7, 8), patients who consumed more than two (male) or one (female) glass of alcohol per day were excluded. After excluding all patients not satisfying the inclusion criteria, the final study population consisted of 87 patients (60 females and 27 males). A summary flow diagram of the population screening process is shown in Figure 1. The study protocol complied with the principles of the Declaration of Helsinki and was approved by the Ethics Committee of the National Institute of Gastroenterology “S. De Bellis” Research Hospital (protocol no. 173/2021). All participants gave prior informed consent to enrollment.

Clinical examination and fluid biomarkers collection

At baseline, all patients underwent a thorough examination of metabolic and biochemical markers. An experienced physician (GDP) conducted an interview probing medical history and lifestyle. Patients who consumed excessive amounts of alcohol, or with viral hepatitis or the human immunodeficiency virus, were excluded. Daily alcohol consumption was assessed through direct questions during the medical history, as follows: "Do you drink more than two glasses of alcohol per day?" for males and "Do you drink more than one glass of alcohol per day?" for females, following American and European daily alcohol consumption guidelines (7, 8), that suggest a threshold of 20 g/day in females and 30 g/day in males. Extemporaneous outpatients diastolic (DBP) and systolic (SBP) pressure was measured three times, in a sitting position using an OMRON M6 automated Blood Pressure monitor. After overnight fasting, blood samples were collected from 08:00 to 09:00 AM. The blood cell count was measured using a Beckman–Coulter Coulter Hematology analyzer (Brea, CA). Serum levels of fasting plasma glucose (FPG), hemoglobin A1c (HbA1c), insulin, total cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, uric acid, and liver markers were measured. Serum insulin concentrations were determined by radioimmunoassay (Behring, Scoppito, Italy), examining duplicate samples. Serum concentrations of TSH, FT3, and FT4 were evaluated using a competitive luminometric method based on the solid-phase antigen luminescent technology (SPALT) principle (LIAISON FT3, FT4, TSH, DiaSorin, Saluggia, Italy). Fasting plasma glucose concentrations were assessed using the glucose oxidase method (Sclavus, Siena, Italy), and plasma lipid concentrations (triglycerides, total cholesterol, and HDL cholesterol) were quantified with an automated colorimetric approach (Hitachi; Boehringer Mannheim, Mannheim, Germany). Glycated hemoglobin (HbA1c) was determined frequently with an Architect c8000 chemical analyzer (Abbott). Serum uric acid was measured by the URICASE/POD method implemented on an autoanalyzer (Boehringer Mannheim), Amino transferase and γ-glutamyl transpeptidase (γGT) were measured with standard routine laboratory methods, and creatinine with an automated system (UniCel Integrated Workstations DxC 660i, Beckman Coulter, Fullerton, CA, USA). Low-density lipoprotein (LDL) cholesterol was calculated using the Friedewald equation (19). Quantitative analysis of serum ferritin was made with DxI/Access using Access Ferritin Reagent Packs (Beckman–Coulter AB, Bromma, Sweden). Serum insulin concentrations were measured by radioimmunoassay (Behring, Scop-pito, Italy) and serum 25 (OH) vitamin D by chemiluminescence (Diasorin Inc, Stillwater, OK, USA). Insulin resistance was assessed using the Homeostasis Model Assessment–Insulin Resistance (HOMA-IR) method (20).

Anthropometric assessment

Two qualified nutritionists (SDN, RZ), trained to conduct clinical procedures consistently, collected all anthropometric measurements, with patients wearing light clothes and barefoot. Variables were all collected simultaneously between 7.00–10.00 AM after overnight fasting. Height was measured to the nearest 0.5 cm using a wall-mounted stadiometer (Seca 711; Seca,
Hamburg, Germany). Body weight was determined to the nearest 0.1 kg using a calibrated balance beam scale (Seca 711; Seca, Hamburg, Germany). BMI was calculated by dividing body weight (kg) by the square of height (m²) and classified according to World Health Organization criteria as normal weight (18.5–24.9 kg/m²), overweight (25.0–29.9 kg/m²), grade I obesity (30.0–34.9 kg/m²), grade II obesity (35.0–39.9 kg/m²), and grade III obesity (≥40.0 kg/m²) (18). Waist circumference (WC) was measured at the narrowest part of the abdomen or in the area between the tenth rib and the iliac crest (minimum circumference).

Bioelectrical Impedance Analysis (BIA) was performed using a single-frequency bioimpedance analyzer (BIA-101 analyzer, 50-kHz frequency; Akern Bioreresearch, Florence, Italy). The instrument is routinely checked with resistors and capacitors of known values. In accordance with European Society of Parenteral and Enteral Nutrition (ESPEN) guidelines (21), all participants were examined supine with their legs spread slightly apart, after refraining from eating, drinking, exercising for 6 h and drinking alcohol for 24 h before the examination. Shoes and socks were removed, and contact areas were scrubbed with alcohol before electrodes placement.

Electrodes (BIATRODES Akern, Florence, Italy) were placed proximal to the phalangeal metacarpal joint on the dorsal surface of the right hand and distal to the transverse arch on the superior surface of the right foot. Sensor electrodes were placed at the midpoint between the distal prominence of the radius and ulna of the right wrist and between the medial and lateral malleoli of the right ankle (22). All measurements were made by a senior nutritionist (SP) under strictly standardized conditions. Whole-body impedance vector components, resistance (R, W) and reactance (Xc, W), were derived and recorded when stable. Then, according to the age, gender, weight and height of each patient, body composition parameters were obtained using the software provided by the manufacturer, including validated (21) predictive equations for total body water (TBW, L), extracellular water (ECW, L), intracellular water (ICW, L), fat-free mass (FFM, kg), MM (kg), Appendicular skeletal muscle mass (ASMM, kg), and body cell mass (BCM, kg). Phase angle (PhA, °) values were also drawn from the reactance ratio vs. electric resistance. A more detailed description of all principles applied to derive bioimpedance measurements has been previously reported (23, 24).

NAFLD assessment by fibroscan

The controlled attenuation parameter (CAP) algorithm implemented in the FibroScan system was chosen to quantify liver fat by measuring the liver attenuation (dB/m) of an ultrasound beam. The method is straightforward, does not require an in-depth knowledge of B-mode ultrasonography, and is increasingly employed as a point-of-care approach in diagnostic examinations of patients with suspected hepatic steatosis. CAP estimates the degree of ultrasound attenuation due to hepatic fat at the standardized frequency of 3.5 MHz by vibration-controlled transient elastography (VCTE), implemented as FibroScan transient elastography (Echosens, Paris, France) (25). Data trials in patients with obesity suggest that CAP measured with FibroScan is comparable to liver biopsy for the detection and quantification of steatosis (26). NAFLD was diagnosed if CAP exceeded 302 dB/m, previously identified as the optimal cutoff for an accurate diagnosis of ≥5% hepatic steatosis using the Youden index, with a sensitivity of 0.80 (95% confidence interval [CI], 0.75–0.84) and specificity of 0.83 (95% CI, 0.69–0.92) (18). Fibrosis ratings were based on liver stiffness using the VCTE approach. The presence of liver fibrosis was recorded in cases with liver stiffness values exceeding 8.2 kPa, and the absence of NAFLD, in cases with a concomitant CAP of <302 dB/m and stiffness of <8.2 kPa.

Liver disease risk estimation algorithms

Prediction algorithms drawn from the literature were included in the descriptive sample analysis to estimate the risk of NAFLD. The FLI, a modeling approach that incorporates BMI, WC, triglycerides, and γGT, was used to determine the likelihood of developing NAFLD (15). The following equation was applied to perform the calculation: \( e^{0.953 \log \text{BMI} + 0.139 \log \text{GGT} + 0.053 \log \text{WC} - 15.745} \). The FAST Score, a modeling algorithm that includes the measurement of liver stiffness (LSM), CAP, and AST, was used to assess the risk of NASH. The following equation was applied: \( e^{-1.65 + 1.07 \log \text{ALT} + 2.66 \times 10^{-6} \text{AST} - 3.33 \times 10^{-1} - 1 + (e^{-1.65 + 1.07 \log \text{LSM}} + 2.66 \times 10^{-6} \text{AST} - 3.33 \times 10^{-1}) \). Lastly, the FIB-4 equation to estimate the risk of liver fibrosis included age, AST, ALT, and platelets, as follows: age [(years) x AST (U/L)]/[(PLT (109/L)] x (ALT [U/L])1/2] (28).

Statistical analysis

The entire sample was subdivided by the CAP cutoff according to NAFLD status (presence/absence), to assess differences in frequency and associations with biochemical, sociodemographic, anthropometric, and dietary variables. The Kolmogorov-Smirnov method was used to test the normality of quantitative variable distributions. For continuous measurements, data are expressed as mean ± standard deviations (M±SD), median (min to max), and frequency and percentages (%) for all categorical variables. A statistical approach based on the null hypothesis significance test (NHST) was excluded, focusing on practical variations in effect size.
Results

The population examined (N = 87) was prevalently female (67%, N = 60), and the age range was 18 to 64 years. NAFLD was diagnosed in 35 patients (40% of the whole sample), according to the threshold CAP value above 302, while only ten patients (11.3% of the entire population) showed liver stiffness values exceeding 8.2 kPa, possibly demonstrating fibrosis.

Table 1 summarizes the main differences in clinical-metabolic, anthropometric, and sociodemographic variables according to NAFLD (presence/absence). Males were slightly more frequently affected by NAFLD than females (51.4% vs. 48.6%, p = 0.01). The NAFLD patients group showed higher DBP, BMI, and WC (p = 0.05, p < 0.01, p < 0.01, respectively). Among metabolic variables, those linked with insulin effect such as serum HbA1c, insulin levels, and HOMA-IR, were higher in the NAFLD group (p = 0.04, p < 0.01, p < 0.01, respectively). Serum transaminases, including AST (p < 0.01) and ALT (p = 0.04), and γGT (p < 0.01), showed the same trend. Concerning the serum lipid profile, the NAFLD group showed lower HDL (p < 0.01) and higher triglyceride levels (p = 0.01) as compared to their counterparts. Creatinine (p = 0.02), uric acid (p < 0.01), and ferritin (p < 0.01) followed the same positive trend in the NAFLD group. Liver stiffness (p < 0.01), FLI (p < 0.01), FAST score (p < 0.01), and CAP (p < 0.01) were higher in the NAFLD group. Findings from the BIA examination revealed significantly higher levels of FM (p = 0.01), FFM (p < 0.01), TBW (p < 0.01), ECW (p < 0.01), and VAT (p < 0.01) in the NAFLD group.

Supplementary Table S1 presents the Spearman correlation matrix findings between CAP values and all other parameters examined in this study. CAP levels were directly associated with BMI, WC, systolic blood pressure, HOMA index, insulin levels, triglycerides, uric acid, AST, ALT, γGT, creatinine, and ferritin, and negatively correlated with HDL concentrations.

These findings were used to select confounding variables in order to build more accurate regression models.

Discussion

The present study examined a population of diabetes-free subjects with obesity, performing transient elastography to identify the metabolic markers most strongly associated to NAFLD, identified by a CAP exceeding 302 dB/m, previously indicated as the optimal cutoff for an accurate fatty liver diagnosis by fibroscan (18). Key findings were the male predominance in the NAFLD subset, as well as higher BMI, abdominal fat, and insulin resistance (quantified by HOMA-IR), and increased blood insulin, HbA1c, triglycerides, uric acid, transaminases, γGT, ferritin, and creatinine levels and lower serum HDL cholesterol concentrations. NAFLD notably afflicts males more than females in accordance with the scientific evidence. In fact, the protective effect of estrogens likely influences this result, as well as the greater male inclination to abdominal obesity, directly related to NAFLD (29).

The metabolic profile of the NAFLD subset was strongly aligned to the body composition, characterized by a marked excess of fat mass and VAT. In this context, a report from the Dionysos and Nutrition Liver Study observed a 6-fold increased risk of NAFLD in subjects with abdominal obesity, regardless of altered liver enzymes (30). The latest guidelines from the Italian Association for the Study of the Liver (AISF), the Italian
### TABLE 1  Description of the whole sample according to the Controlled Attenuation Parameter (CAP) level (CAP < 302 dB/m/CAP ≥ 302 dB/m).

| Parameter                                      | Median (min to max) | Median (min to max) | P value |
|------------------------------------------------|---------------------|---------------------|---------|
| **Proportions (%)**                            |                     |                     |         |
| Age (years)                                    | 43 (18 to 64)       | 44 (19 to 62)       | 0.78    |
| **Gender**                                     |                     |                     |         |
| Female                                         | 43 (82.70)          | 17 (48.60)          | 0.01    |
| Male                                           | 9 (17.30)           | 18 (51.40)          |         |
| **Diastolic blood pressure (mmHg)**            | 77 (55 to 98)       | 84 (50 to 110)      | 0.05    |
| **Systolic blood pressure (mmHg)**             | 129 (105 to 158)    | 130 (110 to 165)    | 0.09    |
| **BMI (Body Mass Index) (Kg/m²)**              | 31 (25.1 to 47.5)   | 35.49 (25.8 to 47.33) | <0.01  |
| **WC (Waist circumference) (cm)**              | 101 (81 to 144)     | 115 (97 to 141)     | <0.01   |
| **Fasting blood glucose (mg/dl)**              | 93 (76 to 118)      | 97 (79 to 156)      | 0.31    |
| **HbA1c (%)**                                  | 5.2 (4.3 to 6.2)    | 5.45 (4.5 to 7.3)   | 0.04    |
| **INSULIN (µU/ml)**                             | 8.79 (2.3 to 38.3)  | 14.9 (4.4 to 54.9)  | <0.01   |
| **GGT (U/L)**                                  | 15 (7 to 93)        | 23 (9 to 89)        | <0.01   |
| **AST (GOT) (U/L)**                            | 21 (10 to 86)       | 33 (13 to 143)      | <0.01   |
| **ALT (GPT) (U/L)**                            | 20 (11 to 47)       | 22 (13 to 58)       | 0.04    |
| **HDL cholesterol (mg/dl)**                    | 52.5 (32 to 109)    | 45 (30 to 76)       | <0.01   |
| **LDL cholesterol (mg/dl)**                    | 140.5 (76 to 219)   | 134 (71 to 224)     | 0.62    |
| **Total cholesterol (mg/dl)**                  | 215.5 (152 to 295)  | 198 (140 to 319)    | 0.23    |
| **Triglycerides (mg/dl)**                      | 85 (25 to 266)      | 117 (48 to 271)     | 0.01    |
| **Creatinine (mg/dl)**                         | 0.7 (0.5 to 1.11)   | 0.8 (0.4 to 1.23)   | 0.02    |
| **Uric Acid (mg/dl)**                          | 4.95 (2.5 to 7.5)   | 5.6 (2.9 to 8.3)    | <0.01   |
| **Ferritin (ng/ml)**                            | 51.7 (3 to 226)     | 103 (10 to 603)     | <0.01   |
| **25-Hydroxyvitamin D (ng/ml)**                | 19.1 (8.3 to 49.4)  | 19.4 (4 to 36.6)    | 0.89    |
| **WBC (White Blood Cells) (10³ cells/mm³)**    | 6.53 (4.01 to 11)   | 6.84 (4.24 to 10.4) | 0.33    |
| **AST score (Fibroscan-AST score)**            | 0.05 (0 to 0.45)    | 0.19 (0.03 to 0.78) | <0.01   |
| **CAP (Controlled Attenuation Parameter) (dB/m)** | 245 (100 to 299)   | 336 (306 to 400)    | <0.01   |
| **Liver stiffness (kPa)**                      | 4.7 (2.3 to 10.4)   | 5.6 (2.7 to 28.5)   | <0.01   |
| **TSH (µU/ml)**                                | 1.62 (0.43 to 4.97) | 2.02 (0.28 to 6.45) | 0.13    |
| **FT3 (pg/ml)**                                | 3.28 (2.6 to 4.24)  | 3.48 (2.71 to 4.79) | 0.06    |
| **FT4 (pg/ml)**                                | 9.2 (6.5 to 15.4)   | 9.5 (6.8 to 14.3)   | 0.16    |
| **FIB-4 (Fibrosis-4 scoring system)**          | 0.64 (0.24 to 1.68) | 0.65 (0.23 to 1.5)  | 0.87    |
| **FLI (Fatty Liver Index)**                    | 57 (14 to 99)       | 87 (42 to 100)      | <0.01   |
| **FLI > 60%**                                  | 15 (7 to 93)        | 23 (9 to 89)        | <0.01   |
| **FFM (Free Fat Mass) (Kg)**                   | 51.32 (39.2 to 77.8) | 63.37 (37.2 to 99.62) | <0.01  |
| **FFMI (Free Fat Mass Index) (Kg/m²)**          | 19.15 (14.6 to 35)  | 21.2 (11.3 to 28.5) | <0.01   |
| **FM (Fat Mass) (Kg)**                         | 32.21 (21.06 to 63.78) | 39.5 (22.4 to 61.56) | 0.01    |
| **FMI (Fat Mass Index) (Kg/m²)**               | 11.9 (6.6 to 45)    | 12.7 (6.3 to 25.4)  | 0.51    |
| **SMMA (Skeletal Muscle Mass) (Kg)**           | 24.95 (18.6 to 39.9) | 31.8 (17.8 to 51.8) | <0.01   |
| **TBW (Total Body Water) (L)**                 | 38.45 (29.6 to 57.5) | 47.7 (27.9 to 74.2) | <0.01   |
| **ECW (Extra Cellular Water) (L)**            | 17.05 (13.4 to 24.7) | 20.6 (12.8 to 31.1) | <0.01   |
| **VAT (Visceral Adipose Tissue) (L)**          | 2.3 (0.1 to 7.91)   | 4.46 (1.6 to 11)    | <0.01   |

**N**: 87.

All data are shown as median (min to max) and as n (%) for proportions.

Wilcoxon U test for independent samples for continuous variables and Chi squared test for categorical ones.

Bold and underlined values indicate the significance of the data.
# Table 2: Linear regression model on Controlled Attenuation Parameter (CAP) as dependent variable and regressor.

| Coefficient | Stand. Err. | CI 95% | p  |
|-------------|-------------|--------|----|
| Uric acid (mg/dl) | 21.36 | 5.5 | 108.34 to 226.38 | < 0.01 |
| Age (years) | 0.45 | 0.55 | -0.63 to 1.54 | 0.41 |
| Gender (male) | 21.57 | 1.8 | -15.28 to 58.42 | 0.25 |
| BMI (Kg/m²) | 3.21 | 1.29 | 0.69 to 5.75 | 0.01 |
| Creatinine (mg/dl) | 0.09 | 0.13 | -0.39 to 0.57 | 0.09 |
| Triglycerides (mg/dl) | 1.65 | 0.77 | -0.12 to 3.15 | 0.03 |
| HOMA-IR | 3.01 | 1.79 | -0.36 to 6.36 | 0.21 |
| AST (U/L) | 5.57 | 2.4 | -0.36 to 5.27 | 0.02 |
| ALT (U/L) | 6.54 | 2.4 | -0.12 to 5.09 | 0.08 |

Bold and underlined values indicate the significance of the data.
pathways. Firstly, uric acid induces fat accumulation via the generation of endoplasmic reticulum stress and SREBP-1c activation in hepatocytes (39). Secondly, hyperuricemic subjects are more prone to develop fructose-induced fatty liver, since uric acid up-regulates fructokinase (KHK) expression in human hepatocytes, thus amplifying the lipogenic effect of fructose (40). Thirdly, higher levels of uric acid may foster the development of insulin resistance by reducing endothelial nitric oxide bioavailability and cell supply (41) and, as previously reported (32), insulin resistance per se may be responsible for liver steatosis.

Strength and limitations

This research features the following strengths. The methodological plausibility and originality of this study findings may be credited to the statistical analysis performed on a consistent cohort from southern Italy, sharing similar traits, and including only individuals taking neither medication nor supplements, thus avoiding any possible pharmacological interference. NAFLD was estimated using a FibroScan controlled attenuation parameter algorithm, still the only guidelines-recommended tool to assess hepatic steatosis when high-cost imaging and biopsy are not available, and widely acknowledged as a point-of-care approach in diagnostic examinations of patients with suspected hepatic steatosis. Some limitations must also be acknowledged. Due to the cross-sectional design, we cannot appreciate any temporal nature of the associations, so prospective observations are required to elucidate any causal relationship. A thorough lifestyle analysis, including genetics and eating habits, would also have been useful, added to the database and to the findings. Moreover, since this is a monocentric study, the results cannot be completely generalized.

Conclusions

We used transient elastography to investigate the association among the presence of NAFLD and clinical, biochemical, and anthropometric parameters in a sample of subjects with overweight and obesity. The metabolic markers found to best illustrate NAFLD are: high BMI and abdominal fat, insulin resistance, and increased blood insulin, HbA1c, triglycerides, transaminases, GT, ferritin, creatinine, and uric acid levels, in contrast to a reduction in serum HDL cholesterol. It was a particularly original finding worthy of note that a single unit increase in uricemia was associated to a rise of CAP by 14 dB/m, paralleling an increase of liver steatosis. On this basis, more attention should be paid to uricemia as a possible marker of an increased risk of developing fatty liver disease in subjects with obesity.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author/s.

Ethics statement

The studies involving human participants were reviewed and approved by Institutional Review Board (or Ethics Committee) of National Institute of Gastroenterology “Saverio de Bellis”, Research Hospital. The patients/participants provided their written informed consent to participate in this study.

Author contributions

SD, RZ, FC, GD, RS, GG, and GP: conceptualization, research, resource provision, data collection, writing original version, and visualization. MD, RR, LL, RC, VG, and SD: research and data collection. GG: funding. RS and RZ: conceptualization, validation, review, and correction. All authors: conceptualization, validation, and visualization. All authors contributed to the article and approved the submitted version.

Funding

Italian Ministry of Health with Ricerca Corrente 2020 funds.

Acknowledgments

The authors thank all the participants and investigators for their efforts.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those
of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories. 1980–2017: a systematic analysis for the global burden of disease study 2017. Lancet. (2018) 392:1736–88. doi: 10.1016/S0140-6736(18)32203-7

2. Cholongitas E, Pavlopoulos I, Papatheodoridi M, Markakis GE, Bouras E, Hadich A-B, et al. Epidemiology of non-alcoholic fatty liver disease in europe: a systematic review and meta-analysis. Ann Gastroenterol Hepatol. (2021) 34:404–14. doi: 10.20528/ag.2021.0604

3. De Nucci S, Zuopo R, Castellana F, Sila A, Triggiani V, Lucio G, et al. Public health response to the SARS-CoV-2 pandemic: concern about ultra-processed food. Foods. (2022) 11:950. doi: 10.3390/foods11090950

4. Zuopo R, Castellana F, Sardone R, Sila A, Giagulli VA, Triggiani V, et al. Preliminary trajectories in dietary behaviors during the COVID-19 pandemic: a public health call to action to face obesity. Int J Environ Res Public Health. (2020) 17:7073. doi: 10.3390/ijerph17197073

5. Marjot T, Moolla A, Cobbold JF, Hodson L, Tomlinson JW. Non-alcoholic fatty liver disease in adults: current concepts in etiology. outcomes. and management. Endocrine Rev. (2020) 41:bzt009. doi: 10.1209/endor/06-09

6. Rinaldi L, Pafundi PC, Galiero R, Caturano A, Morene MV, Silvestri C, et al. Mechanisms of non-alcoholic fatty liver disease in the metabolic syndrome: a narrative review. Antioxidants. (2021) 10:2073. doi: 10.3390/antiox10102070

7. Chalasani N, Younossi Z, Levine J, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology. (2018) 67:328–57. doi: 10.1002/hep.29367

8. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Obes Facts. (2016) 9:65–90. doi: 10.1159/000443344

9. Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current guidelines for the non-alcoholic fatty liver disease: a systematic review with comparative analysis. World J Gastroenterol. (2018) 24:3361–73. doi: 10.3748/wjg.v24.i30.3361

10. Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease in adults 2021: a clinical practice guideline of the Italian association for the study of fatty liver disease in population studies a meta-analysis. J Clin Med Res. (2021) 10:1877. doi: 10.3390/jcm10091877

11. Castera L, Friedrich-Rust M, Loomba R. Non-invasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology. (2019) 156:1264–1281.e4. doi: 10.1053/j.gastro.2018.12.036

12. Eddowes PJ, Sasso M, Allison M, Tochatzis E, Anstee QM, Sheridan D, et al. Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with non-alcoholic fatty liver disease. Gastroenterology. (2019) 156:1717–30. doi: 10.1053/j.gastro.2019.01.042

13. Warnick GR, Knopp RH, Fitzpatrick V, Branson L. Estimating low-density lipoprotein cholesterol by the friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints. Clin Chem. (1990) 36:15–9. doi: 10.1093/clinchem/36.1.15

14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. (1985) 28:412–9. doi: 10.1007/BF00280883

15. Bousard C, Breytere O, Greintick A, Hajaraus M, Scafoglieri A, Perkisus S, et al. Equation models developed with bioelectric impedance analysis tools to assess muscle mass: a systematic review. Clin Nutr ESPEN. (2020) 35:47–62. doi: 10.1016/j.clinexp.2019.09.012

16. Kushner RF. Bioelectrical impedance analysis: a review of principles and applications. J Am Coll Nutr. (1992) 11:199–209. doi: 10.1080/07315724.1992.12098245

17. Kyle Ug, Bosaeus I, De Lorenzo AD, Deurenberg P, Elia M, Gómez JM, et al. Bioelectrical impedance analysis—part ii: utilization in clinical practice. Clin Nutr. (2004) 23:1430–53. doi: 10.1016/j.clnu.2004.09.012

18. Kyle Ug, Bosaeus I, De Lorenzo AD, Deurenberg P, Elia M, Gómez JM, et al. Bioelectrical impedance analysis—part i: review of principles and methods. Clin Nutr. (2004) 23:1226–43. doi: 10.1016/j.clnu.2004.06.004

19. Bergozotti A. Non-invasive assessment of non-alcoholic fatty liver disease: ultrasound and transient elastography. Rev Recent Clin Trials. (2014) 9:170–7. doi: 10.2174/1574887109666141216101630

20. Eilenberg M, Mundt P, Stift J, Langer FB, Prager G, Trauner M, et al. Accuracy of non-invasive liver stiffness measurement and steatosis quantification in patients with severe and morbid obesity. Hepatobiliary Surg Nutr. (2021) 10:610–22. doi: 10.21037/hbsn-20-787

21. Newsome PN, Sasso M, Deeks J, Paredes A, Bourrier J, Chan W-K, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. (2020) 5:362–3. doi: 10.1016/S2352-3315(19)30838-8

22. Sterling RK, Lissen E, Chumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. (2005) 103:1137–25. doi: 10.1002/hep.21178

23. Marchesini G, Bugianesi E, Cavallo P, Franchini F, Bertoli A, et al. Non-alcoholic fatty liver disease in adults 2021: a clinical practice guideline of the Italian association for the study of fatty liver disease in population studies a meta-analysis. J Clin Med Res. (2021) 10:1877. doi: 10.3390/jcm10091877

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnut.2022.1002669/full#supplementary-material
Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). *Dig Liver Dis.* (2022) 54:170–182. doi: 10.1016/j.dld.2021.04.029

32. Xia M-F, Bian H, Gao X. NAFLD and diabetes: two sides of the same coin? Rationale for gene-based personalized NAFLD treatment. *Front Pharmacol.* (2019) 10:877. doi: 10.3389/fphar.2019.00877

33. Acierno C, Caturano A, Pafundi PC, Nevola R, Adinolfi LE, Sassu FC. Non-alcoholic fatty liver disease and type 2 diabetes: pathophysiological mechanism shared between the two faces of the same coin. *Explor Med.* (2020) 1:287–306. doi: 10.37349/emed.2020.00019

34. Dongiovanni P, Stender S, Pietrelli A, Mancina RM, Cespiati A, Petta S, et al. Causal relationship of hepatic fat with liver damage and insulin resistance in non-alcoholic fatty liver. *J Intern Med.* (2018) 283:356–70. doi: 10.1111/jim.12719

35. Watt MJ, Miotto PM, De Nardo W, Pietrelli A, Montgomery MK. The liver as an endocrine organ—linking NAFLD and insulin resistance. *Endocr Rev.* (2019) 40:1367–93. doi: 10.1210/er.2019-00034

36. Di Costanzo A, D’Erasmo L, Polimeni L, Baratta F, Coletta P, Di Martino M, et al. Non-alcoholic fatty liver disease and subclinical atherosclerosis: a comparison of metabolically- versus genetically-driven excess fat hepatic storage. *Atherosclerosis.* (2016) 257:232–9. doi: 10.1016/j.atherosclerosis.2016.12.018

37. Kiapidou S, Liava C, Kalogriotou M, Akriviadis E, Sinakos E. Chronic kidney disease in patients with non-alcoholic fatty liver disease: what the hepatologist should know? *Ann Hepatol.* (2020) 19:134–44. doi: 10.1016/j.aohep.2019.07.013

38. Yang N, Lu Y, Cao L, Lu M. The association between non-alcoholic fatty liver disease and serum ferritin levels in American adults. *J Clin Lab Anal.* (2022) 36:e24225. doi: 10.1002/jcla.24225

39. Choi Y-J, Shin H-S, Choi HS, Park J-W, Jo I, Oh E-S, et al. Uric acid induces fat accumulation via generation of endoplasmic reticulum stress and SREBP-1c activation in hepatocytes. *Lab Invest.* (2014) 94:1114–25. doi: 10.1038/labinvest.2014.98

40. Lanaspa MA, Sanchez-Lozada LG, Cicerchi C, Li N, Roncal-Jimenez CA, Ishimoto T, et al. Uric acid stimulates fructokinase and accelerates fructose metabolism in the development of fatty liver. *PLoS ONE.* (2012) 7:e47948. doi: 10.1371/journal.pone.0047948

41. Li C, Hsieh M-C, Chang S-J. Metabolic syndrome, diabetes, and hyperuricemia. *Curr Opin Rheumatol.* (2013) 25:210–6. doi: 10.1097/BOR.0b013e32835d951e